Abstract
Niemann-Pick disease type C (NPC) is a neurodegenerative lipid storage disorder caused by mutations in NPC1 or NPC2 genes. Loss of function of either protein results in the endosomal accumulation of cholesterol and other lipids. The mechanism of neuro-toxicity induced by the lipid storage has not been well elucidated. Here, we report that NPC1-deficient Chinese hamster ovary cells exhibit increased release of arachidonic acid (AA) and synthesis of prostaglandin E2 compared with wild-type cells. The enhanced release of AA was inhibited by both treatment with the selective inhibitor of cytosolic phospholipase A2α (cPLA2α) and cultivation in lipoprotein-deficient medium. There was no difference in the expression of both cyclooxygenase-1 and -2 between NPC cells and wild-type cells. U18666A, a cholesterol transport-inhibiting agent commonly used to mimic NPC, also increased the release of AA in L929 mouse fibrosarcoma cells. Furthermore, U18666A induced formation of reactive oxygen species, and induced cell death and cell cycle delay/arrest in L929 cells. Interestingly, these responses induced by U18666A were much weaker in cPLA2α knockdown L929 cells. These results suggest that cPLA2α-AA pathway plays important roles in the cytotoxicity and the reactive oxygen species formation in NPC cells.
Keywords: arachidonic acid, cytosolic phospholipase A2α, cytotoxicity, Niemann-Pick disease type C, reactive oxygen species, cell cycle, cholesterol
Current Psychopharmacology
Title:Modulation of Arachidonic Acid Metabolism in Niemann-Pick Disease Type C Cells
Volume: 2
Author(s): Hiroyuki Nakamura
Affiliation:
Keywords: arachidonic acid, cytosolic phospholipase A2α, cytotoxicity, Niemann-Pick disease type C, reactive oxygen species, cell cycle, cholesterol
Abstract: Niemann-Pick disease type C (NPC) is a neurodegenerative lipid storage disorder caused by mutations in NPC1 or NPC2 genes. Loss of function of either protein results in the endosomal accumulation of cholesterol and other lipids. The mechanism of neuro-toxicity induced by the lipid storage has not been well elucidated. Here, we report that NPC1-deficient Chinese hamster ovary cells exhibit increased release of arachidonic acid (AA) and synthesis of prostaglandin E2 compared with wild-type cells. The enhanced release of AA was inhibited by both treatment with the selective inhibitor of cytosolic phospholipase A2α (cPLA2α) and cultivation in lipoprotein-deficient medium. There was no difference in the expression of both cyclooxygenase-1 and -2 between NPC cells and wild-type cells. U18666A, a cholesterol transport-inhibiting agent commonly used to mimic NPC, also increased the release of AA in L929 mouse fibrosarcoma cells. Furthermore, U18666A induced formation of reactive oxygen species, and induced cell death and cell cycle delay/arrest in L929 cells. Interestingly, these responses induced by U18666A were much weaker in cPLA2α knockdown L929 cells. These results suggest that cPLA2α-AA pathway plays important roles in the cytotoxicity and the reactive oxygen species formation in NPC cells.
Export Options
About this article
Cite this article as:
Nakamura Hiroyuki, Modulation of Arachidonic Acid Metabolism in Niemann-Pick Disease Type C Cells, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010058
DOI https://dx.doi.org/10.2174/2211556011302010058 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Chronopharmaceutics Based Modern Colon Specific Drug Delivery Systems
Current Drug Discovery Technologies Recent Advances in Physical Delivery Enhancement of Topical Drugs
Current Pharmaceutical Design Auto-Antibodies As Possible Markers and Mediators of Ischemic, Dilated, and Rhythmic Cardiopathies
Current Drug Targets Thrombolytic Therapy in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science Models in Research of Pharmacoresistant Epilepsy: Present and Future in Development of Antiepileptic Drugs
Current Medicinal Chemistry 5-HT3 Serotonin Receptor Agonists: A Pharmacophoric Journey
Current Medicinal Chemistry - Central Nervous System Agents Novel Immunosuppressive Strategies for Bone Marrow Failure Syndromes: A Focus on Alemtuzumab
Mini-Reviews in Medicinal Chemistry The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology Current Concepts Underlying Benefits of Exercise Training in Congestive Heart Failure Patients
Current Cardiology Reviews Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Joint Diseases and Matrix Metalloproteinases: A Role for MMP-13
Current Pharmaceutical Biotechnology The Importance of Reendothelialization After Arterial Injury
Current Pharmaceutical Design Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Current Cancer Therapy Reviews Regulation of the Metabolism of Polyunsaturated Fatty Acids and Butyrate in Colon Cancer Cells
Current Pharmaceutical Biotechnology Pharmacological Regulation of Dyslipoproteinaemia in Insulin Resistant States
Current Vascular Pharmacology Plasma Protein Binding in Drug Discovery and Development
Combinatorial Chemistry & High Throughput Screening Glycosphingolipid Structure and Function in Membranes
Current Organic Chemistry Biosafety Challenges for Use of Lentiviral Vectors in Gene Therapy
Current Gene Therapy